Impact of Antibiotics, Corticosteroids, and Microbiota on Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer

Impact of Antibiotics, Corticosteroids, and Microbiota on Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Impact of Antibiotics, Corticosteroids, and Microbiota on Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer María Zapata-García, Alba Moratiel, Dolores Isla, Eva Gálvez, and 17 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3899720/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 30 Jun, 2024 Read the published version in Heliyon → Version 1 posted You are reading this latest preprint version Abstract Lung cancer is a leading cause of morbidity and mortality globally, with its high mortality rate attributed mainly to non-small cell lung cancer (NSCLC). Although immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized its treatment, patient response is highly variable and lacking predictive markers. We conducted a prospective study on 55 patients with NSCLC undergoing ICI therapy to identify predictive markers of both response and immune-related adverse events (IrAEs) in the airway microbiota. We also analyzed the clinical evolution and overall survival (OS) with respect to treatments that affect the integrity of the microbiota, such as antibiotics and corticosteroids. Our results demonstrated that respiratory microbiota differ significantly in ICI responders: they have higher alpha diversity values and lower abundance of the Firmicutes phylum and the Streptococcus genus. Employing a logistic regression model, the abundance of Gemella was the major predictor of non-ICI response, whereas Lachnoanaerobaculum was the best predictor of a positive response to ICI. The most relevant results were that antibiotic consumption is linked to a lower ICI response, and the use of corticosteroids correlated with poorer overall survival. Whereas previous studies have focused on gut microbiota, our findings highlight the importance of the respiratory microbiota in predicting the treatment response. Future research should explore microbiota modulation strategies to enhance immunotherapy outcomes. Understanding the impact of antibiotics, corticosteroids, and microbiota on NSCLC immunotherapy will help personalize treatment and improve patient outcomes. lung cancer immunotherapy airway microbiota antibiotics corticosteroids Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 1. INTRODUCTION Cancer is one of the major causes of morbidity and mortality worldwide, with lung cancer being among the most frequently diagnosed ( 1 , 2 ). However, its prevalence is low due to its high mortality rate. Based on GLOBOCAN estimations, 18% of all cancer deaths are due to lung cancer ( 3 ), and among its risk factors, tobacco is the most prevalent followed by radon gas ( 2 ). In terms of treatment, immune-checkpoint inhibitors (ICI) have brought about a radical change, particularly in non-small cell lung cancer (NSCLC), where it has been approved in advanced/metastatic, locally advanced, and adjuvant settings; however, not all patients achieve the same results. In view of this discrepancy in response, attempts have been made to identify therapy-predictive biomarker response ( 4 , 5 ), with some previous studies suggesting the relevance of host-related factors, such as the microbiota, which has been directly linked to ICI effectiveness ( 6 ). The microbiota has been shown to regulate immunotherapy potential by stimulating the anti-tumor immune response, although some microorganisms might metabolize these drugs, thereby inactivating them ( 7 – 10 ). The particularities of the gut microbiota between ICI responders and non-responders have previously been reported ( 11 – 13 ). In addition, the impact of concomitant treatments, such as antibiotics or corticosteroids, in the microbiota composition and finally in the ICI response has been poorly evaluated, despite the current evidence suggesting their implication in the loss of gut microbiota diversity ( 4 , 14 – 17 ). Also, a relationship between immune-related adverse events (IrAEs) and ICI response has been proposed, again without any useful marker for predicting it. The aim of the present study was to prospectively analyze a cohort of patients with NSCLC treated with ICI to decipher microbiota-based markers for both ICI response and toxicity, as well as to estimate the impact of antibiotics and corticosteroids on survival. 2. MATERIALS AND METHODS 2.1. Study design, inclusion, and exclusion criteria This was a prospective, observational study conducted at the Medical Oncology Department of the Lozano Blesa University Hospital Clinic in Zaragoza (Spain), in 55 patients diagnosed with NSCLC and ICI indication, who were consecutively included between April 2019 and October 2020. The inclusion criteria were as follows: patients with locally advanced unresectable and metastatic NSCLC, stages III and IV, with ICI indication (Stage IV patients could receive ICI as a first line of treatment, in monotherapy or combination with chemotherapy, or in subsequent lines of treatment ( 1 ). Patients with unresectable stage III started ICI treatment after radical treatment with concomitant chemotherapy and thoracic radiotherapy, without progressive disease after that treatment. Patients could have been diagnosed de novo or relapsed or progressed to treatment other than ICI); 18 years of age or older; and have an Eastern Cooperative Oncology Group (ECOG) performance status score lower than or equal to 2. The exclusion criteria were as follows: contraindication to receiving ICI; histology different from NSCLC; another concomitant tumor; prior treatment with an ICI antitumor agent; or being on corticosteroid treatment with doses of prednisone ≥ 10 mg/24 hours or equivalent. The protocol was evaluated and approved by the Clinical Research Ethics Committee of Aragón with code (C.I. PI19/052). Prior to their inclusion in the study, all patients gave their informed consent, and baseline blood, saliva, and stool samples were collected before starting immunotherapy treatment. Patients were followed every 2–3 weeks during the treatment administration, as performed in our routine clinical practice, collecting all relevant clinical data for the study, particularly the antibiotic data (the antibiotic cycle, the origin of the infection, and the clinical response), and the corticosteroid (prednisone > 10 mg or its equivalent) consumption. The registration period covered from 2 months prior to ICI start until the end of follow-up. Patients who achieved a response and started follow-up were evaluated every 3 months. During shadowing, tumor response was assessed every 9–12 weeks according to Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) ( 18 ). Treatment safety was assessed by recording adverse events and alterations in analytical parameters. IrAEs were monitored and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (v.5.0)( 19 ). 2.2. Sampling Prior to treatment initiation, a tumor biopsy was routinely collected for programmed death-ligand 1 (PD-L1) determination. Additionally, each patient contributed a respiratory sample (saliva + sputum collected by medical staff) and peripheral blood. Samples were immediately frozen at − 80°C until recruitment was complete. 2.3. Microbiota determination The respiratory samples were slowly defrosted at − 20 ºC for 24 h and 4 ºC for another 24 h, to avoid bacterial death and DNA fragmentation. Total DNA was obtained by the QiaAmp kit (QIAGEN) from the saliva pellet after centrifugation. The bacterial composition was determined by polymerase chain reaction (PCR) amplification of the 16S rDNA V3-V4 region, and PCR products were pooled equally and submitted to massive sequencing (2x300 bp) on a MiSeq (Illumina, San Diego, CA, USA) platform at traslational genomics core support unit (UCAT) -Ramon y Cajal Health Research Institute (Madrid, Spain). The sequence’s quality control was performed with DADA2, with a rarity of 12,000 sequences per sample. Amplicon sequencing variants were obtained by taxonomic assignment with the Silva_132 classifier. Alpha and beta diversity studies were performed, employing the q2-diversity add-on of QIIME2, after normalizing the samples by rarefaction (subsampling without replacement). In addition, a linear effect size discriminant analysis (LEfSe) was performed to assess which taxa explained the differences between groups. Sequence data were deposited in Genbank ( BioProject PRJNA1054537 ). 2.4. Programmed death-ligand 1 biomarker analysis PD-L1 protein expression was evaluated in lung biopsies, naïve to treatment. Samples were considered suitable for PD-L1 staining if they had more than 100 valuable neoplastic cells. PD-L1 expression was assessed with PD-L1 IHC 22C3 pharmaDx, in formalin-fixed tumor samples. PD-L1 expression was confirmed when staining of the tumor cell membrane (at any intensity) was observed. The prespecified expression levels are 1–50% (low expression) or more than 50% (high expression). 2.5. Machine learning analysis The precision of various predictive models was explored using various algorithms, such as logistic regression, random forest, k-nearest neighbors, neural networks, and support vector machines, employing the two data sets: bacterial abundance in saliva and available clinical data. Both data sets were randomly divided into training and test sets. The models’ scoring was evaluated using precision accuracy, and we paid special attention to the f1-score, which allowed us to fine-tune the precision for ICI response and/or toxicity, overall survival (OS), and progression-free survival (PFS). Our data sets are considered relatively small from a machine learning point of view, so we averaged our results over 500 experiments. All models were performed in Python 3.8.10, using the Scikit-learn package. 2.7. Statistical analysis The normal distribution of variables was compared using the Kolmogorov–Smirnov test. For the quantitative variables, distribution normality was checked by the Anderson–Darling test to define the parametric (t-test) and non-parametric (Mann–Whitney) analyses. The correlations between OS (months) and quantitative variables were assessed with Pearson’s or Spearman’s rank correlation, depending on data distribution. For the qualitative variables, Fisher’s exact test was employed. A descriptive analysis of the survival function and cumulative risk function was conducted using the Kaplan–Meier product limit estimator. The study aimed to assess whether the risk function differed based on the presence of certain factors through a bivariate analysis. The Mantel–Haenszel (log-rank) test was employed to compare the risk functions among various groups. The Cox proportional hazards model, also known as Cox regression, was utilized to estimate a model that examines how covariates collectively influence the risk of complications. Probability ( p ) values of < 0.05 were considered significant at a 95% confidence interval. 3. RESULTS 3.1. Patients and treatment Fifty-five Caucasian patients (median age 65 years, 70.9% males) were enrolled, 65.5% of whom had ECOG 0 at diagnosis. Regarding smoking, 3.6% were nonsmokers, compared with 96.4% who were smokers or former smokers. The histology included adenocarcinomas (60%) and squamous cell carcinomas (40%), with stage IV tumor in 70.9% of cases. A total of 25.5% of the patients received ICI and had a locally advanced stage, 32.7% received it as first-line palliative treatment, with the remaining 41.8% in subsequent lines of palliative treatment.pPembrolizumab was the most frequently employed ICI (38.2%) (Table 1 ). Table 1. Descriptive variables in our cohort Characteristics of the Patients at baseline N (55) % Age (median) 65 (62,64-67,39) Sex Male Female 39 16 70.9% 29.1% Race White 55 100% Smoking status Current or former Never 53 2 96.4% 3.6% Body mass index 30 kg/m2 46 9 83.6% 16.4% Eastern Cooperative Oncology Group scale 0 1 36 19 65.5% 34.5% Histologic features Squamous cell carcinoma Adenocarcinoma 22 33 40% 60% Stage III IV 16 39 29.1% 70.9% Treatment indication Locally advanced First-line Successive lines 14 18 23 25.5% 32,7% 41.8% PD-L1 expression 50% Unknown 10 21 16 8 18.2% 38.2% 29.1% 14.5% ICI drug Pembrolizumab Atezolizumab Durvalumab Nivolumab 21 18 14 2 38.2% 32.7% 25.5% 3.6% Best response Complete Partial Stable disease Progression Not evaluable 10 13 12 15 5 18.8% 23.6% 21.8% 27.3% 9.1% Antibiotic treatment Yes No 28 27 50.9% 49.1% Timing of antibiotic use 2 months before – 1 month after ICI start >1 month after ICI start 22 33 40% 60% Corticosteroid treatment Yes No 32 23 58.2% 41.8% Timing of corticosteroid use 2 months before until first ICI cycle After first ICI cycle 9 23 28.1% 71.9% Antimicrobial therapy was required by 50.9% of the patients, and 60% received it after the first month of immunotherapy. Although 60.7% required only one course of antibiotic treatment, up to 7.1% needed four courses. The indications were respiratory (71.5%, of which 28.6% was respiratory infection/pneumonia), urinary (14.3%), or intra-abdominal (3.6%) infections, and were unknown in 7.1% of the cases. Amoxicillin/clavulanic acid, azithromycin, and levofloxacin were the most frequent antimicrobial agents. Corticosteroids were required by 58.2% of the patients, up to 71.9% of them after the first ICI cycle. The reasons for their use were IrAEs (34.4%), cerebral metastases (9.4%), and exacerbations of chronic obstructive pulmonary disease (COPD) (9.4%) (Table 1 ). Globally, 45.5% of patients reported IrAEs (Table 2 ), most of them classified as late IrAEs (> 3 months of ICI); 75% were grade 1–2, and only one patient had grade 4 toxicity (hepatitis). Table 2 Types and grades of immune-related adverse events described in our cohort No. (%) GRADE (%) 1 2 3 4 Infusion reaction 1 (1.8) 100.0 - - - Endocrine 5 (9.1) 40.0 60.0 - - Pneumonitis 6 (10.9) 16.7 66.7 16.7 Colitis 2 (3.6) - 100.0 - - Hepatitis 3 (5.5) 33.3 33.3 - 33.3 Nephritis 4 (7.3) 25.0 25.0 50.0 - Neurologic 1 (1.8) - - 100.0 - Musculoskeletal 5 (9.1) 40.0 20.0 40.0 - Skin 6 (10.9) 50.0 33.3 16.7 - Cardiovascular 1 (1.8) - - 100.0 - Ocular 1 (1.8) 100.0 - - - Other 1 (1.8) - 100.0 - - 3.2. Microbiota analysis After quality control, only one saliva sample was eliminated by the low quantity of reads. Significant differences were observed in the respiratory microbiota between ICI responders and ICI non-responders (Fig. 1 ). ICI responders presented a significantly greater abundance of Fusobacteria and Porphyromonas , whereas in ICI non-responders the Streptococcus genera was significantly more abundant (Fig. 2 ). 3.3. Survival analysis The median overall survival (mOS) was 19 months (95% CI, 11.13 to 26.87), while the median PFS was 10 months (95% CI, 2.81 to 17.19). At the 24-month mark, 36% of the patients were still alive, and 30% had not experienced disease progression. We detected no differences in OS according to sex, smoking status, body mass index, or tumor histology. There were also no significant differences based on age (cut-off 75 years), although there was a tendency toward a shorter OS in older patients. Regarding ECOG, patients with ECOG 0 had a longer OS (27 months) compared with those with ECOG 1 (4 months), and these differences were statistically significant ( p < 0.001) (Fig. 3 ). According to the best achieved response, differences were observed, which were confirmed to be significant. The mOS was 4 months for progressive disease(PR), 20 months for stable disease (EE), 27 months for partial response (RP), and not reached (NR) for complete response (RC). Although no statistically significant differences were found in the analysis of survival and antibiotic exposure, there was a clear trend toward longer survival in patients who did not require antibiotic treatment (mOS 23 months for non-use vs 12 months for use of antibiotics; p = 0.078). Statistically significant differences were not found when analyzing this item based on the number of cycles or on the timing of its use (from 2 months before to 1 month after the start of ICI vs. 1 month after ICI initiation) (Fig. 4 ). Neither of the differences was found when the relationship with PFS was studied. No association between antibiotic use and OS was found; however, non-responders to ICI were exposed to more antibiotics, whereas a higher number of patients without antibiotic use was observed among responders ( p = 0.0439). When analyzing the relationship between OS and corticosteroid use, statistically significant differences were found ( p = 0.011). However, when performing the subgroup analysis based on the reasons for use (COPD, IrAEs, brain metastasis, and others) or timing of use (from 2 months before to 1 month after the first cycle vs. after the first cycle of ICI), these differences did not persist (Fig. 5 ). When analyzing associations between PFS and corticosteroid use, we found no statistically significant differences ( p = 0.846). The same occurred when analyzing the previously mentioned subtypes (Fig. 5 ). The occurrence of IrAEs had a positive correlation with extended OS ( p = 0.051). The median OS of patients with IrAEs was 21 months, whereas in those without such events it was 6 months. However, when we analyzed PFS, the differences observed in the graphs were confirmed in the survival analysis, and these differences were statistically significant ( p = 0.03). No significant differences were found in OS, nor in PFS, based on the type or grade of toxicity. As mentioned earlier, blood samples were also collected. We attempted to find an association between the presence of IrAEs and variation in the percentage of various lymphocyte populations. We analyzed CD8 T lymphocytes (LAG3+, TIM3+), CD4 T lymphocytes, and natural killer cells. No significant differences were found with any of these lymphocyte subpopulations. 3.4. Markers for immune checkpoint inhibitor response Thirty-five (63.6%) patients were considered as ICI responders, with a statistically significant association with longer OS and PFS. A correlation was also found between the presence of IrAEs and the response to immunotherapy. Specifically, there was a higher percentage of patients without immune-related toxicity among non-responders to ICI (Fig. 6 ). The oral microbiota of responders was significantly different from that of non-responders. Significantly higher alpha diversity values were detected in ICI responders, and varied abundance of some microorganisms was identified by LEfSe in saliva (Fig. 7 ). ICI responders presented greater abundance of Bacteroidota to the detriment of Firmicutes , with a fourfold increase in Fusobacterium and Porphyromonas , whereas the abundance of Streptococcus was up to 4.5 times lower (Fig. 8 ). Considering the possibility of predicting response to ICI using information arising from the saliva microbiota, we employed a logistic regression model with parameters c = 1 and a Ridge penalty. Based on our analysis, the abundance of Gemella was the best predictor of no response, whereas Lachnoanaerobaculum was the best predictor of a positive response to ICI. 4. DISCUSSION Our study examined a prospective cohort of 55 patients diagnosed with advanced or metastatic lung cancer who underwent ICI treatment, aiming to evaluate the effect of antibiotics and corticosteroids on the efficacy of ICI and on IrAEs occurrence. We also considered respiratory microbiota as a possible predictive marker of both response to ICI and the occurrence of IrAEs. The baseline characteristics of our patients were similar to those found in the literature ( 20 – 23 ). It is worth mentioning that in some of the referenced trials, there was a lower proportion of patients with ECOG 0 and a higher proportion of non-smokers. The first could be related to the fact that patients with ECOG ≥ 2 are not currently suitable for ICI treatment ( 24 , 25 ). The second difference could be explained by the presence of more actionable alterations found in non-smoking patients, making them ineligible for ICI treatment ( 20 , 23 , 26 – 28 ). With respect to survival and response rate, in our study, we had a median PFS of 10 months, an mOS of 19 months, and an overall response rate of 42.4%. These data are similar to those previously reported in clinical trials with comparable samples performed with ICI ( 23 , 27 , 29 – 32 ). Not all patients respond in the same way to ICI. Just as the response is not homogeneous, neither is the development of IrAEs ( 25 , 33 ). IrAEs are reported in up to 80% of patients receiving ICI in monotherapy and in up to 95% of those receiving combinations with ICI. Regarding concomitant treatments, several studies have examined the influence of the use of proton pump inhibitors, antibiotics, or corticosteroids, among others, on the efficacy of immunotherapy. Most associate the use of these treatments with shorter survival and a poorer treatment response ( 17 , 23 , 34 – 38 ). An illustrative instance of this phenomenon is the retrospective review conducted by Tinsley et al . In their cohort of 291 patients, a subset of 92 received antibiotics, and they exhibited both a reduced PFS and OS in comparison to those who did not receive it (median OS 10.4 months vs. 21.7 months) ( 39 ). These results are closely parallel to those observed within our cohort, with an mOS of 12 months among individuals who used antibiotics, in contrast to 23 months in those who did not. Our findings reveal a disparity in PFS and OS greater than that reported in the meta-analysis conducted by Lurienne et al . In their study, antibiotic use yielded a reduction of 1.2 months in PFS (not statistically significant) and 6.7 months in OS. However, in contrast to our study, the differences in OS were statistically significant. This disparity can be potentially elucidated by the inclusion of ECOG 2 patients (an attribute not encompassed within our cohort) and by the ICI indication. In this meta-analysis, the majority of patients received ICI in second and subsequent lines of therapy, in contrast to our dataset, in which the majority of patients underwent administration of ICI as first-line or adjuvant therapy ( 40 ). Regarding the relationship between corticosteroids and OS, our results are consistent with those published in the literature ( 41 – 43 ). However, our study did not reach statistical significance in PFS or in the different subgroups, as other studies such as Arbour et al. , among others, have achieved ( 41 ). It has been suggested that de-structuring of the microbiota, particularly those produced by the antibiotics, could have a negative impact on ICI´s efficacy ( 34 , 39 , 40 ). Insights from retrospective studies have taught us that antibiotics and corticosteroids produce dysbiosis in the gut microbiota when used during immunotherapy. This could cause poorer outcomes in these cases. However, there are still many aspects that deserve further investigation ( 37 ), including the impact of each family of antimicrobials. Previous studies have shown that exposure to antibiotics in the month preceding the start of ICI therapy is associated with shorter OS and a poorer response. This aligns with research suggesting that the microbiota takes approximately 4–6 weeks to restore after exposure. However, a recent study has been published suggesting that even antibiotic exposure in the year prior to the initiation of ICI could have deleterious effects ( 35 ). In the same way, the use of corticosteroids was related to a higher amount of Actinomyces in saliva. Similar results were published by Georgiou in 2022, which showed a tendency to a higher proportion of Actinobacteria in the salivary microbiota of those patients diagnosed with lung cancer, without the use of concomitant medication that could condition the results ( 7 ). In a systematic review published in 2021, patients receiving corticosteroids for respiratory tract diseases found a significant increase in the salivary microbiota of Actinobacteria , mainly at the expense of the family Microbacteriaceae , but without highlighting differences with respect to the species Actinomyces ( 36 ). Our cohort study also assessed differences in microbiota composition between ICI responders and non-responders. Following the same trend as the results presented by McCulloch et al . (patients with melanoma treated with anti-PD-1), our study also observed the enrichment of the genera Streptococcus in non-responders’ microbiota ( 13 ). As previously demonstrated in other studies, ICI have been associated with a reduction in Bacteroidetes and Firmicutes within the gut microbiota. However, within our cohort, we observed an increase in Firmicutes abundance among individuals exhibiting a subpar response to ICI ( 44 ). These findings appear to contradict the literature suggesting that supplementation with Bifidobacterium could enhance ICI response. However, some studies have reported results consistent with ours regarding the increase in Bacteroidetes among individuals with a poor ICI response and, consequently, a shorter OS ( 45 ). We are aware of the detrimental effects of antibiotics and corticosteroids on the efficacy of ICI. The composition of salivary microbiota might have been influenced by concurrent medication use, potentially contributing to differences between responders and non-responders. A critical question is determining which microbiota composition is more favorable for ICI effectiveness, and how it can be restored to a normal composition following antibiotic or corticosteroid treatment ( 46 ). Some trials have demonstrated that certain commensal bacteria, such as Akkermansia muciniphila , are more abundant in stool samples from responders ( 44 , 47 ). However, this pattern did not hold true in our cohort. Taxonomic features associated with improved response during ICI treatment should be further characterized in larger prospective trials. The characterization of salivary microbiota in patients with lung cancer (given its close association) warrants investigation ( 46 ). Additional studies are needed to identify microbiome-modulating therapies, such as fecal transplantation and dietary or supplement interventions, to reverse the dysbiosis induced by administered treatments, thereby enhancing the ICI response. 5. CONCLUSIONS In our cohort, the use of corticosteroids was significantly associated with a poorer OS, whereas exposition to antibiotics is linked to a diminished response to ICI, although we did not observe a significant association with OS. The absence of a statistically significant difference in OS between patients who received or did not receive antibiotics suggests that their use does not directly impact long-term survival outcomes. Nevertheless, the efficacy of ICI could be influenced by the specific antibiotic and their specific impact on the bacterial populations. Possible mechanisms underlying this relationship include alterations in the microbiota, including a decreased abundance of commensal microorganisms and changes in the taxonomic characteristics of the salivary microbiota, as observed in our cohort. Regarding IrAEs, we did not find a significant difference in survival based on their presence or absence, although there is a trend toward improved PFS in the absence of IrAEs. However, similar to what occurs with antibiotics, we observed a better response to ICIs in those who have not experienced IrAEs. Concordant with that previously reported for the gut microbiota, the airway microbiota appears to play a substantial role in the response to ICI. Its composition significantly differs between responders and non-responders. Responders have a greater abundance of the phyla Bacteroidota and the genera Fusobacterium and Porphyromonas , and a lower population of the phyla Firmicutes and Streptococcus . Specifically, reversing the alterations caused by corticosteroids and antibiotics to achieve taxonomic characteristics of the microbiota similar to those of responders could lead to improved responses to ICI and enhanced survival outcomes in patients with NSCLC. Declarations We would like to acknowledge the patients and the Biobank of the Aragon Health System integrated in the Spanish National Biobanks Network (PT20/00112) for their collaboration. Funding This research was supported by CIBER - Consorcio Centro de Investigación Biomédica en Red - (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R), Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (PID2020-113963RB-I00). It was also supported by a Personalized and Precision Medicine grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, funded by NextGenerationEU funds from the European Union that finance the actions of the the Resilience and Recovery Facility. Autor A.R-L. has received research support from Ramón y Cajal RYC2022-036627-I (AR-L). AUTHOR CONTRIBUTIONS All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by María Zapata-García, Alba Moratiel, Eva Gálvez, Marta Gascón-Ruíz, Andrea Sesma, Raquel Barbero, Javier Galdeano, Rosa del Campo, Maitane Ocáriz and Mara Cruellas. The first draft of the manuscript was written by María Zapata-García and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. References Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358–76. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20:624–39. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. Huang X-Z, Gao P, Song Y-X, Xu Y, Sun J-X, Chen X-W, et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. Oncoimmunology. 2019;00(00):1665973. Yi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):1–10. Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022;28(2):315–24. Georgiou K, Marinov B, Farooqi AA, Gazouli M. Gut microbiota in lung cancer: Where do we stand? Int J Mol Sci. 2021;22(19):1–17. Georgiou K. Gut Microbiota in Obesity and Bariatric Surgery: Where Do We Stand? In Gut Microbiome-Related Diseases and Therapies. In: Gazouli M, Theodoropoulos G, editors. The Microbiomes of Humans, Animals, Plants, and The Environment. Springer I. Switzerland; 2021. p. 183–227. Peterson SN, Bradley LM, Ronai ZA. The Gut Microbiome: An Unexpected Player in Cancer Immunity. Curr Opin Neurobiol. 2020;62:48–52. Pitt JM, Vétizou M, Waldschmitt N, Kroemer G, Chamaillard M, Boneca IG, et al. Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. Cancer Res. 2016;76:4602–7. Routy B, Derosa L, Daille R, Roberti PM, Zitvogel L. The impact of the intestinal microbiota in therapeutic Impact du microbiote intestinal dans les re le cancer. C R Biol. 2020;341(2018):284–9. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut Microbiome Influences Efficacy of PD-1–Based Immunotherapy against Epithelial Tumors. Science (80- ). 2018;359:91–7. McCulloch J, Davar D, Rodrigues R, Badger J, Fang J, Cole A, et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med. 2022;28(3):545–56. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med [Internet]. 2016;8(1). Available from: http://dx.doi.org/10.1186/s13073-016-0294-z Giles A, Hutchinson M-K, Sonnermann H, Jung J, Fecci P. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1). Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 2019;4(1):1–8. Cruellas M, Yubero A, Zapata M, Galvez EM, Gascón M, Isla D, et al. How could antibiotics, probiotics, and corticoids modify microbiota and its influence in cancer immune checkpoint inhibitors: A review. Infect Immun. 2021;89(9):1–7. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol [Internet]. 2022;17(2):289–308. Available from: https://doi.org/10.1016/j.jtho.2021.09.010 Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040–51. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J. Atezolizumab Versus Docetaxel in Patients With Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. Lancet. 2017;389(10066):255–65. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Ankit B. Non-Small Cell Lung Cancer. NCCN Guidel [Internet]. 2022;version 3. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073–126. Papadimitrakopoulou V, Cobo M, Bordon R, Al. E. IMPOWER132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. In: IASLC 19th World Conference on Lung Cancer 2018; abstr. 2018. p. OA05.07. Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J. Pembrolizumab Versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. Lancet. 2016;387(10027):1540–50. De Castro GJ, Kudaba I, Wu Y, Lopes G, Kowalski DM. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non – Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ‡ 1 % in the KEYNOTE-042 Study clinical trial updates abstract. J Clin Oncol. 2022;0(0):0. Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, et al. Nivolumab versus Docetaxel in Advancer Nonsquamous Non-Small-Cell Lung Caner. N Engl J Med. 2015;373(17):1627–39. Herbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328–39. Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab Versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–33. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. J Thorac Oncol. 2020;15(2):288–93. Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok T, Reck M, et al. Pooled analyses of immune-related adverse events and efficacy from the phase 3 trials IMpower130, IMpower132 and IMpower150. 2021. Zalcman G, Crespin A, Cervesi J, Al E. Update of systematic reviews and meta-analyses studying the association between antibiotic use and clinical outcomes of cancer patients treated with immune checkpoint inhibitors. In: ESMO Immuno-Oncology Virtual Congres. 2020. p. 50P. Eng L, Sutradhar R, Niu Y, Liu N, Liu Y, Kaliwal Y, et al. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. J Clin Oncol. 2023;41(17):3122–34. Hartmann JE, Albrich WC, Dmitrijeva M, Kahlert CR. The Effects of Corticosteroids on the Respiratory Microbiome: A Systematic Review. Front Med. 2021;8(March). Meriggi F, Zaniboni A. Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature. Cancer Immunol Immunother. 2021;70(6):1511–7. Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525–31. Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, et al. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. Oncologist. 2020;25(1):55–63. Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, et al. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2020;15(7):1147-1159. Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–8. De Giglio A, Mezquita L, Auclin E, Blanc-Durand F, El-Amarti L, Caramella C, et al. Impact of early introduction of steroids on immune- checkpoint inhibitors ( ICI ) in patients with advanced non- small-cell lung cancer Disclosure information Laura Mezquita. Paris; 2020. Drakaki A, Luhn P, Wakelee H, Dhillon PK, Kent M, Shim J, et al. Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice. Ann Oncol. 2019;30(Supplement 11):xi16–7. Sevcikova A, Izoldova N, Stevurkova V, Kasperova B, Chovanec M, Ciernikova S, et al. The impact of the microbiome on resistance to cancer treatment with chemotherapeutic agents and immunotherapy. Int J Mol Sci. 2022;23(1). Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews M. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science (80- ). 2018;359:97–103. Alkan G, Senturk Oztas N, Turna ZH, Ozguroglu M. Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. Lung Cancer. 2023;184. Derosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437–44. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 30 Jun, 2024 Read the published version in Heliyon → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3899720","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":269947466,"identity":"83e7b4d0-32f3-4e8f-b397-c5fa89d8d950","order_by":0,"name":"María Zapata-García","email":"data:image/png;base64,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","orcid":"","institution":"Oncology Department, Lozano Blesa University Hospital Clinic, 50009 Zaragoza","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"María","middleName":"","lastName":"Zapata-García","suffix":""},{"id":269947467,"identity":"7140ee21-bc42-40fb-bbd2-7956f81cc541","order_by":1,"name":"Alba Moratiel","email":"","orcid":"","institution":"Oncology Department, Lozano Blesa University Hospital Clinic, 50009 Zaragoza","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Alba","middleName":"","lastName":"Moratiel","suffix":""},{"id":269947468,"identity":"a7cb27c0-e8b4-40aa-a962-8279c4402dbe","order_by":2,"name":"Dolores Isla","email":"","orcid":"","institution":"Univesity Hospital Lozano Blesa","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Dolores","middleName":"","lastName":"Isla","suffix":""},{"id":269947469,"identity":"7ae2aab5-2697-4738-b93b-8dc9562c5401","order_by":3,"name":"Eva Gálvez","email":"","orcid":"","institution":"Institute of Carbochemistry (ICB), CSIC","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Eva","middleName":"","lastName":"Gálvez","suffix":""},{"id":269947470,"identity":"154f2e88-e479-48d2-b356-535a3050e3b1","order_by":4,"name":"Marta Gascón-Ruiz","email":"","orcid":"","institution":"Miguel Servet University Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Marta","middleName":"","lastName":"Gascón-Ruiz","suffix":""},{"id":269947471,"identity":"3933e43f-9e26-40b6-ab3b-5bc87a4c3866","order_by":5,"name":"Andrea Sesma","email":"","orcid":"","institution":"Navarra University Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Andrea","middleName":"","lastName":"Sesma","suffix":""},{"id":269947472,"identity":"26ab5529-55e3-4e3f-ad6b-7b6ac03690f4","order_by":6,"name":"Raquel Barbero","email":"","orcid":"","institution":"Ramón y Cajal University Hospital and IRYCIS","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Raquel","middleName":"","lastName":"Barbero","suffix":""},{"id":269947473,"identity":"0ccfa4fb-6f2e-43b1-aaa1-6071d4b20d51","order_by":7,"name":"Javier Galeano","email":"","orcid":"","institution":"Polytechnic University of Madrid","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Javier","middleName":"","lastName":"Galeano","suffix":""},{"id":269947474,"identity":"b2c43abc-159b-4161-8279-3e282247688e","order_by":8,"name":"Rosa del Campo","email":"","orcid":"","institution":"Ramón y Cajal University Hospital and IRYCIS. CIBERINFEC","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Rosa","middleName":"del","lastName":"Campo","suffix":""},{"id":269947475,"identity":"85a33e59-1696-4d1b-9d45-469af1387317","order_by":9,"name":"Maitane Ocáriz","email":"","orcid":"","institution":"Univesity Hospital Lozano Blesa","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Maitane","middleName":"","lastName":"Ocáriz","suffix":""},{"id":269947476,"identity":"6642983a-d008-4b66-a3f8-dcd4e0f06f2e","order_by":10,"name":"Elisa Quílez","email":"","orcid":"","institution":"Oncology Department, Lozano Blesa University Hospital Clinic, 50009 Zaragoza","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Elisa","middleName":"","lastName":"Quílez","suffix":""},{"id":269947477,"identity":"2958c7f0-2b9a-4661-af70-647b93b1354d","order_by":11,"name":"Mara Cruellas","email":"","orcid":"","institution":"Vall d´Hebrón University Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Mara","middleName":"","lastName":"Cruellas","suffix":""},{"id":269947478,"identity":"39ba8e0f-8dd9-45d2-89f2-f3f4c732a863","order_by":12,"name":"Ariel Remírez-Labrada","email":"","orcid":"","institution":"Health Research Institute of Aragón (IIS Aragón)","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ariel","middleName":"","lastName":"Remírez-Labrada","suffix":""},{"id":269947479,"identity":"f9bd6cd5-1e3a-4cf3-bb29-e817a0498be2","order_by":13,"name":"Julian Pardo","email":"","orcid":"","institution":"Center for Biomedical Research in the Network of Infectious Diseases (CIBERINFEC), Carlos III Health Institute (ISCIII)","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Julian","middleName":"","lastName":"Pardo","suffix":""},{"id":269947480,"identity":"fba709ec-d7c8-45d1-9193-319195d51dc6","order_by":14,"name":"Luis Martínez-Lostao","email":"","orcid":"","institution":"Microbiology Department, Preventive Medicine and Public Health, University of Zaragoza","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Luis","middleName":"","lastName":"Martínez-Lostao","suffix":""},{"id":269947481,"identity":"e566b879-66ab-465f-8149-0dba7de22e32","order_by":15,"name":"María Pilar Domingo","email":"","orcid":"","institution":"Institute of Carbochemistry (ICB-CSIC)","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"María","middleName":"Pilar","lastName":"Domingo","suffix":""},{"id":269947482,"identity":"95555a85-1de3-46b9-b94f-784b7ccdc521","order_by":16,"name":"Patricia Esteban","email":"","orcid":"","institution":"Health Research Institute of Aragón (IIS Aragón)","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Patricia","middleName":"","lastName":"Esteban","suffix":""},{"id":269947483,"identity":"1f31bd4c-0bba-4f9f-876e-e529da88ed30","order_by":17,"name":"Irene Torres-Ramón","email":"","orcid":"","institution":"Univesity Hospital Lozano Blesa","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Irene","middleName":"","lastName":"Torres-Ramón","suffix":""},{"id":269947484,"identity":"a82aae3b-53ad-4e63-a86b-39e3c086fb3d","order_by":18,"name":"Alfonso Yubero","email":"","orcid":"","institution":"Univesity Hospital Lozano Blesa","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Alfonso","middleName":"","lastName":"Yubero","suffix":""},{"id":269947485,"identity":"20ae28fc-c4c7-440e-bf83-c8c300ccd515","order_by":19,"name":"Jose Ramón Paño","email":"","orcid":"","institution":"Infectious Diseases Department, Lozano Blesa University Hospital Clinic, 50009, Zaragoza","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jose","middleName":"Ramón","lastName":"Paño","suffix":""},{"id":269947486,"identity":"567bc1e1-1953-4765-8f6e-18e0b6389b17","order_by":20,"name":"Rodrigo Lastra","email":"","orcid":"","institution":"Oncology Department, Lozano Blesa University Hospital Clinic, 50009 Zaragoza","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Rodrigo","middleName":"","lastName":"Lastra","suffix":""}],"badges":[],"createdAt":"2024-01-26 10:50:21","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3899720/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3899720/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1016/j.heliyon.2024.e33684","type":"published","date":"2024-07-01T00:49:33+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":50387203,"identity":"d6a95bbb-a9a6-480b-b084-5f25cd040923","added_by":"auto","created_at":"2024-01-30 17:54:55","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":59992,"visible":true,"origin":"","legend":"\u003cp\u003eMedians of the bacterial phyla in the respiratory sample. Differences between responders and non-responders to immune checkpoint inhibitors.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-3899720/v1/4c0f5fba2642c73c48e522ac.png"},{"id":50387204,"identity":"834eb184-77b5-4132-a655-86b34646d17b","added_by":"auto","created_at":"2024-01-30 17:54:55","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":261562,"visible":true,"origin":"","legend":"\u003cp\u003eDifferences in the respiratory microbiota between immune checkpoint inhibitor responders and non-responders by linear effect size discriminant analysis\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-3899720/v1/540261dcf830615dc58519d9.png"},{"id":50387207,"identity":"fa97e1a3-1bc6-4722-a558-f5591902448e","added_by":"auto","created_at":"2024-01-30 17:54:56","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":112604,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan–Meier survival curve graphs. A) Survival curves based on Eastern Cooperative Oncology Group scale. B) Survival curves based on tumor stage. C) Survival curves based on the type of immunotherapy. D) Survival curves based on the best-achieved response. The numerical data and p-values are specified in the text above.\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-3899720/v1/bc9d4d98d0265045418d5246.png"},{"id":50388714,"identity":"33015b1c-d4bf-4315-a5d9-4b866f5426e2","added_by":"auto","created_at":"2024-01-30 18:10:55","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":62132,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan–Meier overall survival curve graphs. A) Survival curves based on use or non-use of antibiotics. B) Survival curves based on cycles of antibiotics. C) Survival curves based on timing of use.\u003c/p\u003e","description":"","filename":"floatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-3899720/v1/66a5d214541cfbc346d2a7bd.png"},{"id":50387210,"identity":"30a8b297-50b1-4fc6-b90f-4ce5a70f3314","added_by":"auto","created_at":"2024-01-30 17:54:56","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":543220,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan–Meier overall survival and progression-free survival curve graphs. A) Survival curves based on the use or non-use of corticosteroids. B) Survival curves based on reasons for its use. C) Survival curves based on timing. D) Progression-free survival based on use or non-use of corticosteroids. E) Progression-free survival based on reasons for its use. F) Progression free survival based on timing.\u003c/p\u003e","description":"","filename":"floatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-3899720/v1/d630972ff34cb1716888e182.png"},{"id":50388248,"identity":"1c185938-ff52-4b14-b20b-13ea644406a0","added_by":"auto","created_at":"2024-01-30 18:02:56","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":164719,"visible":true,"origin":"","legend":"\u003cp\u003eCorrelation between immune checkpoint inhibitor response and immune-related adverse events\u003c/p\u003e","description":"","filename":"floatimage6.png","url":"https://assets-eu.researchsquare.com/files/rs-3899720/v1/5b62e2029f2e7498b776838b.png"},{"id":50387209,"identity":"eca0890a-b2b6-4c57-a9bb-2d81572bd5bd","added_by":"auto","created_at":"2024-01-30 17:54:56","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":199456,"visible":true,"origin":"","legend":"\u003cp\u003eAlpha and beta diversity among immune checkpoint inhibitor responders and non-responders in saliva.\u003c/p\u003e","description":"","filename":"floatimage7.png","url":"https://assets-eu.researchsquare.com/files/rs-3899720/v1/e2237dd3ff9c0318697b89f2.png"},{"id":50388246,"identity":"73a56403-0a71-48a4-9c0c-cbffeadd332f","added_by":"auto","created_at":"2024-01-30 18:02:55","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":22385,"visible":true,"origin":"","legend":"\u003cp\u003eAbundance of the most relevant bacterial genera between responders and non-responders.\u003c/p\u003e","description":"","filename":"floatimage8.png","url":"https://assets-eu.researchsquare.com/files/rs-3899720/v1/58f36e5f420e1090c2713f43.png"},{"id":59532704,"identity":"0a2cfcb3-8b50-483b-a4c6-fbcef58986d2","added_by":"auto","created_at":"2024-07-03 00:49:39","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2174941,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3899720/v1/16a72c1d-bd4c-4611-bf87-27decd5f550f.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Impact of Antibiotics, Corticosteroids, and Microbiota on Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer","fulltext":[{"header":"1. INTRODUCTION","content":"\u003cp\u003eCancer is one of the major causes of morbidity and mortality worldwide, with lung cancer being among the most frequently diagnosed (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). However, its prevalence is low due to its high mortality rate. Based on GLOBOCAN estimations, 18% of all cancer deaths are due to lung cancer (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e), and among its risk factors, tobacco is the most prevalent followed by radon gas (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). In terms of treatment, immune-checkpoint inhibitors (ICI) have brought about a radical change, particularly in non-small cell lung cancer (NSCLC), where it has been approved in advanced/metastatic, locally advanced, and adjuvant settings; however, not all patients achieve the same results. In view of this discrepancy in response, attempts have been made to identify therapy-predictive biomarker response (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e), with some previous studies suggesting the relevance of host-related factors, such as the microbiota, which has been directly linked to ICI effectiveness (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe microbiota has been shown to regulate immunotherapy potential by stimulating the anti-tumor immune response, although some microorganisms might metabolize these drugs, thereby inactivating them (\u003cspan additionalcitationids=\"CR8 CR9\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). The particularities of the gut microbiota between ICI responders and non-responders have previously been reported (\u003cspan additionalcitationids=\"CR12\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e). In addition, the impact of concomitant treatments, such as antibiotics or corticosteroids, in the microbiota composition and finally in the ICI response has been poorly evaluated, despite the current evidence suggesting their implication in the loss of gut microbiota diversity (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan additionalcitationids=\"CR15 CR16\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). Also, a relationship between immune-related adverse events (IrAEs) and ICI response has been proposed, again without any useful marker for predicting it.\u003c/p\u003e \u003cp\u003eThe aim of the present study was to prospectively analyze a cohort of patients with NSCLC treated with ICI to decipher microbiota-based markers for both ICI response and toxicity, as well as to estimate the impact of antibiotics and corticosteroids on survival.\u003c/p\u003e"},{"header":"2. MATERIALS AND METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1. Study design, inclusion, and exclusion criteria\u003c/h2\u003e \u003cp\u003eThis was a prospective, observational study conducted at the Medical Oncology Department of the Lozano Blesa University Hospital Clinic in Zaragoza (Spain), in 55 patients diagnosed with NSCLC and ICI indication, who were consecutively included between April 2019 and October 2020.\u003c/p\u003e \u003cp\u003eThe inclusion criteria were as follows: patients with locally advanced unresectable and metastatic NSCLC, stages III and IV, with ICI indication (Stage IV patients could receive ICI as a first line of treatment, in monotherapy or combination with chemotherapy, or in subsequent lines of treatment (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Patients with unresectable stage III started ICI treatment after radical treatment with concomitant chemotherapy and thoracic radiotherapy, without progressive disease after that treatment. Patients could have been diagnosed \u003cem\u003ede novo\u003c/em\u003e or relapsed or progressed to treatment other than ICI); 18 years of age or older; and have an Eastern Cooperative Oncology Group (ECOG) performance status score lower than or equal to 2.\u003c/p\u003e \u003cp\u003eThe exclusion criteria were as follows: contraindication to receiving ICI; histology different from NSCLC; another concomitant tumor; prior treatment with an ICI antitumor agent; or being on corticosteroid treatment with doses of prednisone\u0026thinsp;\u0026ge;\u0026thinsp;10 mg/24 hours or equivalent.\u003c/p\u003e \u003cp\u003e The protocol was evaluated and approved by the Clinical Research Ethics Committee of Arag\u0026oacute;n with code (C.I. PI19/052). Prior to their inclusion in the study, all patients gave their informed consent, and baseline blood, saliva, and stool samples were collected before starting immunotherapy treatment.\u003c/p\u003e \u003cp\u003ePatients were followed every 2\u0026ndash;3 weeks during the treatment administration, as performed in our routine clinical practice, collecting all relevant clinical data for the study, particularly the antibiotic data (the antibiotic cycle, the origin of the infection, and the clinical response), and the corticosteroid (prednisone\u0026thinsp;\u0026gt;\u0026thinsp;10 mg or its equivalent) consumption. The registration period covered from 2 months prior to ICI start until the end of follow-up.\u003c/p\u003e \u003cp\u003ePatients who achieved a response and started follow-up were evaluated every 3 months. During shadowing, tumor response was assessed every 9\u0026ndash;12 weeks according to Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) (\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e). Treatment safety was assessed by recording adverse events and alterations in analytical parameters. IrAEs were monitored and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (v.5.0)(\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2. Sampling\u003c/h2\u003e \u003cp\u003ePrior to treatment initiation, a tumor biopsy was routinely collected for programmed death-ligand 1 (PD-L1) determination. Additionally, each patient contributed a respiratory sample (saliva\u0026thinsp;+\u0026thinsp;sputum collected by medical staff) and peripheral blood. Samples were immediately frozen at \u0026minus;\u0026thinsp;80\u0026deg;C until recruitment was complete.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3. Microbiota determination\u003c/h2\u003e \u003cp\u003eThe respiratory samples were slowly defrosted at \u0026minus;\u0026thinsp;20 \u0026ordm;C for 24 h and 4 \u0026ordm;C for another 24 h, to avoid bacterial death and DNA fragmentation. Total DNA was obtained by the QiaAmp kit (QIAGEN) from the saliva pellet after centrifugation. The bacterial composition was determined by polymerase chain reaction (PCR) amplification of the 16S rDNA V3-V4 region, and PCR products were pooled equally and submitted to massive sequencing (2x300 bp) on a MiSeq (Illumina, San Diego, CA, USA) platform at traslational genomics core support unit (UCAT) -Ramon y Cajal Health Research Institute (Madrid, Spain). The sequence\u0026rsquo;s quality control was performed with DADA2, with a rarity of 12,000 sequences per sample. Amplicon sequencing variants were obtained by taxonomic assignment with the Silva_132 classifier. Alpha and beta diversity studies were performed, employing the q2-diversity add-on of QIIME2, after normalizing the samples by rarefaction (subsampling without replacement). In addition, a linear effect size discriminant analysis (LEfSe) was performed to assess which taxa explained the differences between groups. Sequence data were deposited in Genbank (\u003cem\u003eBioProject PRJNA1054537\u003c/em\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.4. Programmed death-ligand 1 biomarker analysis\u003c/h2\u003e \u003cp\u003ePD-L1 protein expression was evaluated in lung biopsies, na\u0026iuml;ve to treatment. Samples were considered suitable for PD-L1 staining if they had more than 100 valuable neoplastic cells. PD-L1 expression was assessed with PD-L1 IHC 22C3 pharmaDx, in formalin-fixed tumor samples. PD-L1 expression was confirmed when staining of the tumor cell membrane (at any intensity) was observed. The prespecified expression levels are 1\u0026ndash;50% (low expression) or more than 50% (high expression).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.5. Machine learning analysis\u003c/h2\u003e \u003cp\u003eThe precision of various predictive models was explored using various algorithms, such as logistic regression, random forest, k-nearest neighbors, neural networks, and support vector machines, employing the two data sets: bacterial abundance in saliva and available clinical data. Both data sets were randomly divided into training and test sets. The models\u0026rsquo; scoring was evaluated using precision accuracy, and we paid special attention to the f1-score, which allowed us to fine-tune the precision for ICI response and/or toxicity, overall survival (OS), and progression-free survival (PFS). Our data sets are considered relatively small from a machine learning point of view, so we averaged our results over 500 experiments. All models were performed in Python 3.8.10, using the Scikit-learn package.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e2.7. Statistical analysis\u003c/h2\u003e \u003cp\u003eThe normal distribution of variables was compared using the Kolmogorov\u0026ndash;Smirnov test. For the quantitative variables, distribution normality was checked by the Anderson\u0026ndash;Darling test to define the parametric (t-test) and non-parametric (Mann\u0026ndash;Whitney) analyses.\u003c/p\u003e \u003cp\u003eThe correlations between OS (months) and quantitative variables were assessed with Pearson\u0026rsquo;s or Spearman\u0026rsquo;s rank correlation, depending on data distribution. For the qualitative variables, Fisher\u0026rsquo;s exact test was employed.\u003c/p\u003e \u003cp\u003eA descriptive analysis of the survival function and cumulative risk function was conducted using the Kaplan\u0026ndash;Meier product limit estimator. The study aimed to assess whether the risk function differed based on the presence of certain factors through a bivariate analysis. The Mantel\u0026ndash;Haenszel (log-rank) test was employed to compare the risk functions among various groups. The Cox proportional hazards model, also known as Cox regression, was utilized to estimate a model that examines how covariates collectively influence the risk of complications. Probability (\u003cem\u003ep\u003c/em\u003e) values of \u0026lt;\u0026thinsp;0.05 were considered significant at a 95% confidence interval.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. RESULTS","content":"\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\n \u003ch2\u003e3.1. Patients and treatment\u003c/h2\u003e\n \u003cp\u003eFifty-five Caucasian patients (median age 65 years, 70.9% males) were enrolled, 65.5% of whom had ECOG 0 at diagnosis. Regarding smoking, 3.6% were nonsmokers, compared with 96.4% who were smokers or former smokers. The histology included adenocarcinomas (60%) and squamous cell carcinomas (40%), with stage IV tumor in 70.9% of cases.\u003c/p\u003e\n \u003cp\u003eA total of 25.5% of the patients received ICI and had a locally advanced stage, 32.7% received it as first-line palliative treatment, with the remaining 41.8% in subsequent lines of palliative treatment.pPembrolizumab was the most frequently employed ICI (38.2%) (Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eTable 1.\u003c/strong\u003e Descriptive variables in our cohort \u0026nbsp;\u003c/p\u003e\n \u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"551\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCharacteristics of the Patients at baseline\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eN (55)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003e%\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eAge (median) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e65 (62,64-67,39)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eSex\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e Male \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Female \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e39\u003c/p\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e70.9%\u003c/p\u003e\n \u003cp\u003e29.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eRace\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e White \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e100%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eSmoking status\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e Current or former\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Never \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e53\u003c/p\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e96.4%\u003c/p\u003e\n \u003cp\u003e3.6% \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eBody mass index\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e \u0026lt;30 kg/m2 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;\u0026gt;30 kg/m2 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e83.6%\u003c/p\u003e\n \u003cp\u003e16.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eEastern Cooperative Oncology Group scale\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e 0 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;1 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e65.5%\u003c/p\u003e\n \u003cp\u003e34.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eHistologic features\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e Squamous cell carcinoma\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Adenocarcinoma\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e40%\u003c/p\u003e\n \u003cp\u003e60%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eStage\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e III \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;IV \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003cp\u003e39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e29.1%\u003c/p\u003e\n \u003cp\u003e70.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eTreatment indication\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003eLocally advanced\u003c/li\u003e\n \u003cli\u003eFirst-line\u003c/li\u003e\n \u003cli\u003eSuccessive lines \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e25.5%\u003c/p\u003e\n \u003cp\u003e32,7% \u0026nbsp;\u003c/p\u003e\n \u003cp\u003e41.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003ePD-L1 expression\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e\u0026lt;1%\u003c/li\u003e\n \u003cli\u003e1-49%\u003c/li\u003e\n \u003cli\u003e\u0026gt;50%\u003c/li\u003e\n \u003cli\u003eUnknown\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e18.2%\u003c/p\u003e\n \u003cp\u003e38.2%\u003c/p\u003e\n \u003cp\u003e29.1%\u003c/p\u003e\n \u003cp\u003e14.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eICI drug\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003ePembrolizumab\u003c/li\u003e\n \u003cli\u003eAtezolizumab\u003c/li\u003e\n \u003cli\u003eDurvalumab\u003c/li\u003e\n \u003cli\u003eNivolumab\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e38.2%\u003c/p\u003e\n \u003cp\u003e32.7%\u003c/p\u003e\n \u003cp\u003e25.5%\u003c/p\u003e\n \u003cp\u003e3.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eBest response\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003eComplete\u003c/li\u003e\n \u003cli\u003ePartial\u003c/li\u003e\n \u003cli\u003eStable disease\u003c/li\u003e\n \u003cli\u003eProgression\u003c/li\u003e\n \u003cli\u003eNot evaluable\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e18.8%\u003c/p\u003e\n \u003cp\u003e23.6%\u003c/p\u003e\n \u003cp\u003e21.8%\u003c/p\u003e\n \u003cp\u003e27.3%\u003c/p\u003e\n \u003cp\u003e9.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eAntibiotic treatment\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003eYes\u003c/li\u003e\n \u003cli\u003eNo\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e50.9%\u003c/p\u003e\n \u003cp\u003e49.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eTiming of antibiotic use\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e2 months before \u0026ndash; 1 month after ICI start\u003c/li\u003e\n \u003cli\u003e\u0026gt;1 month after ICI start\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e40%\u003c/p\u003e\n \u003cp\u003e60%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eCorticosteroid treatment\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003eYes\u003c/li\u003e\n \u003cli\u003eNo\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e58.2%\u003c/p\u003e\n \u003cp\u003e41.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"55.43478260869565%\" valign=\"top\"\u003e\n \u003cp\u003eTiming of corticosteroid use\u003c/p\u003e\n \u003cul start=\"17\"\u003e\n \u003cli\u003e2 months before until first\u003csup\u003e\u0026nbsp;\u003c/sup\u003eICI cycle\u003c/li\u003e\n \u003cli\u003eAfter first ICI cycle\u003c/li\u003e\n \u003c/ul\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.195652173913043%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.369565217391305%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e28.1%\u003c/p\u003e\n \u003cp\u003e71.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n \u003cp\u003eAntimicrobial therapy was required by 50.9% of the patients, and 60% received it after the first month of immunotherapy. Although 60.7% required only one course of antibiotic treatment, up to 7.1% needed four courses. The indications were respiratory (71.5%, of which 28.6% was respiratory infection/pneumonia), urinary (14.3%), or intra-abdominal (3.6%) infections, and were unknown in 7.1% of the cases. Amoxicillin/clavulanic acid, azithromycin, and levofloxacin were the most frequent antimicrobial agents.\u003c/p\u003e\n \u003cp\u003eCorticosteroids were required by 58.2% of the patients, up to 71.9% of them after the first ICI cycle. The reasons for their use were IrAEs (34.4%), cerebral metastases (9.4%), and exacerbations of chronic obstructive pulmonary disease (COPD) (9.4%) (Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eGlobally, 45.5% of patients reported IrAEs (Table \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e), most of them classified as late IrAEs (\u0026gt;\u0026thinsp;3 months of ICI); 75% were grade 1\u0026ndash;2, and only one patient had grade 4 toxicity (hepatitis).\u003c/p\u003e\n \u003cp\u003e\u003c/p\u003e\u0026nbsp;\u003ctable id=\"Tab2\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cp\u003eTypes and grades of immune-related adverse events described in our cohort\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eNo. (%)\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" colspan=\"4\"\u003e\n \u003cp\u003eGRADE (%)\u003c/p\u003e\n \u003cp\u003e1 2 3 4\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eInfusion reaction\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e1 (1.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eEndocrine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e5 (9.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e40.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e60.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePneumonitis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e6 (10.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e66.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eColitis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e2 (3.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eHepatitis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e3 (5.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e33.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e33.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e33.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNephritis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e4 (7.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e25.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e25.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNeurologic\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e1 (1.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eMusculoskeletal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e5 (9.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e40.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e20.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e40.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSkin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e6 (10.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e33.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eCardiovascular\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e1 (1.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eOcular\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e1 (1.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e1 (1.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n \u003cp\u003e\u003c/p\u003e\n \u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\n \u003ch2\u003e3.2. Microbiota analysis\u003c/h2\u003e\n \u003cp\u003eAfter quality control, only one saliva sample was eliminated by the low quantity of reads. Significant differences were observed in the respiratory microbiota between ICI responders and ICI non-responders (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). ICI responders presented a significantly greater abundance of \u003cem\u003eFusobacteria\u003c/em\u003e and \u003cem\u003ePorphyromonas\u003c/em\u003e, whereas in ICI non-responders the \u003cem\u003eStreptococcus\u003c/em\u003e genera was significantly more abundant (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\n \u003ch2\u003e3.3. Survival analysis\u003c/h2\u003e\n \u003cp\u003eThe median overall survival (mOS) was 19 months (95% CI, 11.13 to 26.87), while the median PFS was 10 months (95% CI, 2.81 to 17.19). At the 24-month mark, 36% of the patients were still alive, and 30% had not experienced disease progression.\u003c/p\u003e\n \u003cp\u003eWe detected no differences in OS according to sex, smoking status, body mass index, or tumor histology. There were also no significant differences based on age (cut-off 75 years), although there was a tendency toward a shorter OS in older patients. Regarding ECOG, patients with ECOG 0 had a longer OS (27 months) compared with those with ECOG 1 (4 months), and these differences were statistically significant (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eAccording to the best achieved response, differences were observed, which were confirmed to be significant. The mOS was 4 months for progressive disease(PR), 20 months for stable disease (EE), 27 months for partial response (RP), and not reached (NR) for complete response (RC).\u003c/p\u003e\n \u003cp\u003eAlthough no statistically significant differences were found in the analysis of survival and antibiotic exposure, there was a clear trend toward longer survival in patients who did not require antibiotic treatment (mOS 23 months for non-use vs 12 months for use of antibiotics; \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.078). Statistically significant differences were not found when analyzing this item based on the number of cycles or on the timing of its use (from 2 months before to 1 month after the start of ICI vs. 1 month after ICI initiation) (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003e). Neither of the differences was found when the relationship with PFS was studied.\u003c/p\u003e\n \u003cp\u003eNo association between antibiotic use and OS was found; however, non-responders to ICI were exposed to more antibiotics, whereas a higher number of patients without antibiotic use was observed among responders (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0439).\u003c/p\u003e\n \u003cp\u003eWhen analyzing the relationship between OS and corticosteroid use, statistically significant differences were found (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.011). However, when performing the subgroup analysis based on the reasons for use (COPD, IrAEs, brain metastasis, and others) or timing of use (from 2 months before to 1 month after the first cycle vs. after the first cycle of ICI), these differences did not persist (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eWhen analyzing associations between PFS and corticosteroid use, we found no statistically significant differences (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.846). The same occurred when analyzing the previously mentioned subtypes (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eThe occurrence of IrAEs had a positive correlation with extended OS (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.051). The median OS of patients with IrAEs was 21 months, whereas in those without such events it was 6 months. However, when we analyzed PFS, the differences observed in the graphs were confirmed in the survival analysis, and these differences were statistically significant (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.03). No significant differences were found in OS, nor in PFS, based on the type or grade of toxicity.\u003c/p\u003e\n \u003cp\u003eAs mentioned earlier, blood samples were also collected. We attempted to find an association between the presence of IrAEs and variation in the percentage of various lymphocyte populations. We analyzed CD8 T lymphocytes (LAG3+, TIM3+), CD4 T lymphocytes, and natural killer cells. No significant differences were found with any of these lymphocyte subpopulations.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\n \u003ch2\u003e3.4. Markers for immune checkpoint inhibitor response\u003c/h2\u003e\n \u003cp\u003eThirty-five (63.6%) patients were considered as ICI responders, with a statistically significant association with longer OS and PFS. A correlation was also found between the presence of IrAEs and the response to immunotherapy. Specifically, there was a higher percentage of patients without immune-related toxicity among non-responders to ICI (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eThe oral microbiota of responders was significantly different from that of non-responders. Significantly higher alpha diversity values were detected in ICI responders, and varied abundance of some microorganisms was identified by LEfSe in saliva (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eICI responders presented greater abundance of \u003cem\u003eBacteroidota\u003c/em\u003e to the detriment of \u003cem\u003eFirmicutes\u003c/em\u003e, with a fourfold increase in \u003cem\u003eFusobacterium\u003c/em\u003e and \u003cem\u003ePorphyromonas\u003c/em\u003e, whereas the abundance of \u003cem\u003eStreptococcus\u003c/em\u003e was up to 4.5 times lower (Fig. \u003cspan class=\"InternalRef\"\u003e8\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eConsidering the possibility of predicting response to ICI using information arising from the saliva microbiota, we employed a logistic regression model with parameters c\u0026thinsp;=\u0026thinsp;1 and a Ridge penalty. Based on our analysis, the abundance of \u003cem\u003eGemella\u003c/em\u003e was the best predictor of no response, whereas \u003cem\u003eLachnoanaerobaculum\u003c/em\u003e was the best predictor of a positive response to ICI.\u003c/p\u003e\n\u003c/div\u003e"},{"header":"4. DISCUSSION","content":"\u003cp\u003eOur study examined a prospective cohort of 55 patients diagnosed with advanced or metastatic lung cancer who underwent ICI treatment, aiming to evaluate the effect of antibiotics and corticosteroids on the efficacy of ICI and on IrAEs occurrence. We also considered respiratory microbiota as a possible predictive marker of both response to ICI and the occurrence of IrAEs.\u003c/p\u003e \u003cp\u003eThe baseline characteristics of our patients were similar to those found in the literature (\u003cspan additionalcitationids=\"CR21 CR22\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e). It is worth mentioning that in some of the referenced trials, there was a lower proportion of patients with ECOG 0 and a higher proportion of non-smokers. The first could be related to the fact that patients with ECOG\u0026thinsp;\u0026ge;\u0026thinsp;2 are not currently suitable for ICI treatment (\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e). The second difference could be explained by the presence of more actionable alterations found in non-smoking patients, making them ineligible for ICI treatment (\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan additionalcitationids=\"CR27\" citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eWith respect to survival and response rate, in our study, we had a median PFS of 10 months, an mOS of 19 months, and an overall response rate of 42.4%. These data are similar to those previously reported in clinical trials with comparable samples performed with ICI (\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan additionalcitationids=\"CR30 CR31\" citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e). Not all patients respond in the same way to ICI. Just as the response is not homogeneous, neither is the development of IrAEs (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e). IrAEs are reported in up to 80% of patients receiving ICI in monotherapy and in up to 95% of those receiving combinations with ICI.\u003c/p\u003e \u003cp\u003eRegarding concomitant treatments, several studies have examined the influence of the use of proton pump inhibitors, antibiotics, or corticosteroids, among others, on the efficacy of immunotherapy. Most associate the use of these treatments with shorter survival and a poorer treatment response (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan additionalcitationids=\"CR35 CR36 CR37\" citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e). An illustrative instance of this phenomenon is the retrospective review conducted by Tinsley \u003cem\u003eet al\u003c/em\u003e. In their cohort of 291 patients, a subset of 92 received antibiotics, and they exhibited both a reduced PFS and OS in comparison to those who did not receive it (median OS 10.4 months vs. 21.7 months) (\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e). These results are closely parallel to those observed within our cohort, with an mOS of 12 months among individuals who used antibiotics, in contrast to 23 months in those who did not.\u003c/p\u003e \u003cp\u003eOur findings reveal a disparity in PFS and OS greater than that reported in the meta-analysis conducted by Lurienne \u003cem\u003eet al\u003c/em\u003e. In their study, antibiotic use yielded a reduction of 1.2 months in PFS (not statistically significant) and 6.7 months in OS. However, in contrast to our study, the differences in OS were statistically significant. This disparity can be potentially elucidated by the inclusion of ECOG 2 patients (an attribute not encompassed within our cohort) and by the ICI indication. In this meta-analysis, the majority of patients received ICI in second and subsequent lines of therapy, in contrast to our dataset, in which the majority of patients underwent administration of ICI as first-line or adjuvant therapy (\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eRegarding the relationship between corticosteroids and OS, our results are consistent with those published in the literature (\u003cspan additionalcitationids=\"CR42\" citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e). However, our study did not reach statistical significance in PFS or in the different subgroups, as other studies such as Arbour \u003cem\u003eet al.\u003c/em\u003e, among others, have achieved (\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eIt has been suggested that de-structuring of the microbiota, particularly those produced by the antibiotics, could have a negative impact on ICI\u0026acute;s efficacy (\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e). Insights from retrospective studies have taught us that antibiotics and corticosteroids produce dysbiosis in the gut microbiota when used during immunotherapy. This could cause poorer outcomes in these cases. However, there are still many aspects that deserve further investigation (\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e), including the impact of each family of antimicrobials.\u003c/p\u003e \u003cp\u003ePrevious studies have shown that exposure to antibiotics in the month preceding the start of ICI therapy is associated with shorter OS and a poorer response. This aligns with research suggesting that the microbiota takes approximately 4\u0026ndash;6 weeks to restore after exposure. However, a recent study has been published suggesting that even antibiotic exposure in the year prior to the initiation of ICI could have deleterious effects (\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e). In the same way, the use of corticosteroids was related to a higher amount of \u003cem\u003eActinomyces\u003c/em\u003e in saliva.\u003c/p\u003e \u003cp\u003eSimilar results were published by Georgiou in 2022, which showed a tendency to a higher proportion of \u003cem\u003eActinobacteria\u003c/em\u003e in the salivary microbiota of those patients diagnosed with lung cancer, without the use of concomitant medication that could condition the results (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e). In a systematic review published in 2021, patients receiving corticosteroids for respiratory tract diseases found a significant increase in the salivary microbiota of \u003cem\u003eActinobacteria\u003c/em\u003e, mainly at the expense of the family \u003cem\u003eMicrobacteriaceae\u003c/em\u003e, but without highlighting differences with respect to the species \u003cem\u003eActinomyces\u003c/em\u003e (\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eOur cohort study also assessed differences in microbiota composition between ICI responders and non-responders. Following the same trend as the results presented by McCulloch \u003cem\u003eet al\u003c/em\u003e. (patients with melanoma treated with anti-PD-1), our study also observed the enrichment of the genera \u003cem\u003eStreptococcus\u003c/em\u003e in non-responders\u0026rsquo; microbiota (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eAs previously demonstrated in other studies, ICI have been associated with a reduction in \u003cem\u003eBacteroidetes\u003c/em\u003e and \u003cem\u003eFirmicutes\u003c/em\u003e within the gut microbiota. However, within our cohort, we observed an increase in \u003cem\u003eFirmicutes\u003c/em\u003e abundance among individuals exhibiting a subpar response to ICI (\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e). These findings appear to contradict the literature suggesting that supplementation with \u003cem\u003eBifidobacterium\u003c/em\u003e could enhance ICI response. However, some studies have reported results consistent with ours regarding the increase in \u003cem\u003eBacteroidetes\u003c/em\u003e among individuals with a poor ICI response and, consequently, a shorter OS (\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eWe are aware of the detrimental effects of antibiotics and corticosteroids on the efficacy of ICI. The composition of salivary microbiota might have been influenced by concurrent medication use, potentially contributing to differences between responders and non-responders. A critical question is determining which microbiota composition is more favorable for ICI effectiveness, and how it can be restored to a normal composition following antibiotic or corticosteroid treatment (\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e). Some trials have demonstrated that certain commensal bacteria, such as \u003cem\u003eAkkermansia muciniphila\u003c/em\u003e, are more abundant in stool samples from responders (\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e, \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e). However, this pattern did not hold true in our cohort. Taxonomic features associated with improved response during ICI treatment should be further characterized in larger prospective trials. The characterization of salivary microbiota in patients with lung cancer (given its close association) warrants investigation (\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e). Additional studies are needed to identify microbiome-modulating therapies, such as fecal transplantation and dietary or supplement interventions, to reverse the dysbiosis induced by administered treatments, thereby enhancing the ICI response.\u003c/p\u003e"},{"header":"5. CONCLUSIONS","content":"\u003cp\u003eIn our cohort, the use of corticosteroids was significantly associated with a poorer OS, whereas exposition to antibiotics is linked to a diminished response to ICI, although we did not observe a significant association with OS. The absence of a statistically significant difference in OS between patients who received or did not receive antibiotics suggests that their use does not directly impact long-term survival outcomes. Nevertheless, the efficacy of ICI could be influenced by the specific antibiotic and their specific impact on the bacterial populations. Possible mechanisms underlying this relationship include alterations in the microbiota, including a decreased abundance of commensal microorganisms and changes in the taxonomic characteristics of the salivary microbiota, as observed in our cohort.\u003c/p\u003e \u003cp\u003eRegarding IrAEs, we did not find a significant difference in survival based on their presence or absence, although there is a trend toward improved PFS in the absence of IrAEs. However, similar to what occurs with antibiotics, we observed a better response to ICIs in those who have not experienced IrAEs.\u003c/p\u003e \u003cp\u003eConcordant with that previously reported for the gut microbiota, the airway microbiota appears to play a substantial role in the response to ICI. Its composition significantly differs between responders and non-responders. Responders have a greater abundance of the phyla \u003cem\u003eBacteroidota\u003c/em\u003e and the genera \u003cem\u003eFusobacterium\u003c/em\u003e and \u003cem\u003ePorphyromonas\u003c/em\u003e, and a lower population of the phyla \u003cem\u003eFirmicutes\u003c/em\u003e and \u003cem\u003eStreptococcus\u003c/em\u003e. Specifically, reversing the alterations caused by corticosteroids and antibiotics to achieve taxonomic characteristics of the microbiota similar to those of responders could lead to improved responses to ICI and enhanced survival outcomes in patients with NSCLC.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eWe would like to acknowledge the patients and the Biobank of the Aragon Health System integrated in the Spanish National Biobanks Network (PT20/00112) for their collaboration.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research was supported by CIBER - Consorcio Centro de Investigación Biomédica en Red - (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea \u0026ndash; NextGenerationEU, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R), Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (PID2020-113963RB-I00).\u0026nbsp;It was also supported by a Personalized and Precision Medicine grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovaci\u0026oacute;n, funded by NextGenerationEU funds from the European Union that finance the actions of the the Resilience and Recovery Facility. Autor A.R-L.\u0026nbsp;has received research support from Ram\u0026oacute;n y Cajal RYC2022-036627-I (AR-L).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAUTHOR CONTRIBUTIONS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Mar\u0026iacute;a Zapata-Garc\u0026iacute;a, Alba Moratiel, Eva G\u0026aacute;lvez, Marta Gasc\u0026oacute;n-Ru\u0026iacute;z, Andrea Sesma, Raquel Barbero, Javier Galdeano, Rosa del Campo, Maitane Oc\u0026aacute;riz and Mara Cruellas. The first draft of the manuscript was written by Mar\u0026iacute;a Zapata-Garc\u0026iacute;a and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eHendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358\u0026ndash;76. \u003c/li\u003e\n\u003cli\u003eLeiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20:624\u0026ndash;39. \u003c/li\u003e\n\u003cli\u003eSiegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u0026ndash;48. \u003c/li\u003e\n\u003cli\u003eHuang X-Z, Gao P, Song Y-X, Xu Y, Sun J-X, Chen X-W, et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. Oncoimmunology. 2019;00(00):1665973. \u003c/li\u003e\n\u003cli\u003eYi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):1\u0026ndash;10. \u003c/li\u003e\n\u003cli\u003eDerosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022;28(2):315\u0026ndash;24. \u003c/li\u003e\n\u003cli\u003eGeorgiou K, Marinov B, Farooqi AA, Gazouli M. Gut microbiota in lung cancer: Where do we stand? Int J Mol Sci. 2021;22(19):1\u0026ndash;17. \u003c/li\u003e\n\u003cli\u003eGeorgiou K. Gut Microbiota in Obesity and Bariatric Surgery: Where Do We Stand? In Gut Microbiome-Related Diseases and Therapies. In: Gazouli M, Theodoropoulos G, editors. The Microbiomes of Humans, Animals, Plants, and The Environment. Springer I. Switzerland; 2021. p. 183\u0026ndash;227. \u003c/li\u003e\n\u003cli\u003ePeterson SN, Bradley LM, Ronai ZA. The Gut Microbiome: An Unexpected Player in Cancer Immunity. Curr Opin Neurobiol. 2020;62:48\u0026ndash;52. \u003c/li\u003e\n\u003cli\u003ePitt JM, V\u0026eacute;tizou M, Waldschmitt N, Kroemer G, Chamaillard M, Boneca IG, et al. Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. Cancer Res. 2016;76:4602\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eRouty B, Derosa L, Daille R, Roberti PM, Zitvogel L. The impact of the intestinal microbiota in therapeutic Impact du microbiote intestinal dans les re le cancer. C R Biol. 2020;341(2018):284\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eRouty B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u0026egrave;re R, et al. Gut Microbiome Influences Efficacy of PD-1\u0026ndash;Based Immunotherapy against Epithelial Tumors. Science (80- ). 2018;359:91\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eMcCulloch J, Davar D, Rodrigues R, Badger J, Fang J, Cole A, et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med. 2022;28(3):545\u0026ndash;56. \u003c/li\u003e\n\u003cli\u003eLangdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med [Internet]. 2016;8(1). Available from: http://dx.doi.org/10.1186/s13073-016-0294-z\u003c/li\u003e\n\u003cli\u003eGiles A, Hutchinson M-K, Sonnermann H, Jung J, Fecci P. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1). \u003c/li\u003e\n\u003cli\u003eFuc\u0026agrave; G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 2019;4(1):1\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eCruellas M, Yubero A, Zapata M, Galvez EM, Gasc\u0026oacute;n M, Isla D, et al. How could antibiotics, probiotics, and corticoids modify microbiota and its influence in cancer immune checkpoint inhibitors: A review. Infect Immun. 2021;89(9):1\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eEisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u0026ndash;47. \u003c/li\u003e\n\u003cli\u003eBrahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u0026ndash;68. \u003c/li\u003e\n\u003cli\u003ePaz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol [Internet]. 2022;17(2):289\u0026ndash;308. Available from: https://doi.org/10.1016/j.jtho.2021.09.010\u003c/li\u003e\n\u003cli\u003ePaz-Ares L, Luft A, Vicente D, Tafreshi A, G\u0026uuml;m\u0026uuml;ş M, Mazi\u0026egrave;res J, et al. Pembrolizumab plus Chemotherapy for Squamous Non\u0026ndash;Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040\u0026ndash;51. \u003c/li\u003e\n\u003cli\u003eGandhi L, Rodr\u0026iacute;guez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u0026ndash;92. \u003c/li\u003e\n\u003cli\u003eRittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J. Atezolizumab Versus Docetaxel in Patients With Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. Lancet. 2017;389(10066):255\u0026ndash;65. \u003c/li\u003e\n\u003cli\u003eEttinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Ankit B. Non-Small Cell Lung Cancer. NCCN Guidel [Internet]. 2022;version 3. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf\u003c/li\u003e\n\u003cli\u003eSchneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073\u0026ndash;126. \u003c/li\u003e\n\u003cli\u003ePapadimitrakopoulou V, Cobo M, Bordon R, Al. E. IMPOWER132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. In: IASLC 19th World Conference on Lung Cancer 2018; abstr. 2018. p. OA05.07. \u003c/li\u003e\n\u003cli\u003eHerbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J. Pembrolizumab Versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. Lancet. 2016;387(10027):1540\u0026ndash;50. \u003c/li\u003e\n\u003cli\u003eDe Castro GJ, Kudaba I, Wu Y, Lopes G, Kowalski DM. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non \u0026ndash; Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u0026Dagger; 1 % in the KEYNOTE-042 Study clinical trial updates abstract. J Clin Oncol. 2022;0(0):0. \u003c/li\u003e\n\u003cli\u003eBorghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, et al. Nivolumab versus Docetaxel in Advancer Nonsquamous Non-Small-Cell Lung Caner. N Engl J Med. 2015;373(17):1627\u0026ndash;39. \u003c/li\u003e\n\u003cli\u003eHerbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328\u0026ndash;39. \u003c/li\u003e\n\u003cli\u003eReck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab Versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u0026ndash;33. \u003c/li\u003e\n\u003cli\u003eGray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC\u0026mdash;Update from PACIFIC. J Thorac Oncol. 2020;15(2):288\u0026ndash;93. \u003c/li\u003e\n\u003cli\u003eSocinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok T, Reck M, et al. Pooled analyses of immune-related adverse events and efficacy from the phase 3 trials IMpower130, IMpower132 and IMpower150. 2021. \u003c/li\u003e\n\u003cli\u003eZalcman G, Crespin A, Cervesi J, Al E. Update of systematic reviews and meta-analyses studying the association between antibiotic use and clinical outcomes of cancer patients treated with immune checkpoint inhibitors. In: ESMO Immuno-Oncology Virtual Congres. 2020. p. 50P. \u003c/li\u003e\n\u003cli\u003eEng L, Sutradhar R, Niu Y, Liu N, Liu Y, Kaliwal Y, et al. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. J Clin Oncol. 2023;41(17):3122\u0026ndash;34. \u003c/li\u003e\n\u003cli\u003eHartmann JE, Albrich WC, Dmitrijeva M, Kahlert CR. The Effects of Corticosteroids on the Respiratory Microbiome: A Systematic Review. Front Med. 2021;8(March). \u003c/li\u003e\n\u003cli\u003eMeriggi F, Zaniboni A. Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature. Cancer Immunol Immunother. 2021;70(6):1511\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eChalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525\u0026ndash;31. \u003c/li\u003e\n\u003cli\u003eTinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, et al. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. Oncologist. 2020;25(1):55\u0026ndash;63. \u003c/li\u003e\n\u003cli\u003eLurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, et al. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2020;15(7):1147-1159. \u003c/li\u003e\n\u003cli\u003eArbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u0026ndash;small-cell lung cancer. J Clin Oncol. 2018;36(28):2872\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eDe Giglio A, Mezquita L, Auclin E, Blanc-Durand F, El-Amarti L, Caramella C, et al. Impact of early introduction of steroids on immune- checkpoint inhibitors ( ICI ) in patients with advanced non- small-cell lung cancer Disclosure information Laura Mezquita. Paris; 2020. \u003c/li\u003e\n\u003cli\u003eDrakaki A, Luhn P, Wakelee H, Dhillon PK, Kent M, Shim J, et al. Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice. Ann Oncol. 2019;30(Supplement 11):xi16\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eSevcikova A, Izoldova N, Stevurkova V, Kasperova B, Chovanec M, Ciernikova S, et al. The impact of the microbiome on resistance to cancer treatment with chemotherapeutic agents and immunotherapy. Int J Mol Sci. 2022;23(1). \u003c/li\u003e\n\u003cli\u003eGopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews M. Gut microbiome modulates response to anti\u0026ndash;PD-1 immunotherapy in melanoma patients. Science (80- ). 2018;359:97\u0026ndash;103. \u003c/li\u003e\n\u003cli\u003eAlkan G, Senturk Oztas N, Turna ZH, Ozguroglu M. Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. Lung Cancer. 2023;184. \u003c/li\u003e\n\u003cli\u003eDerosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437\u0026ndash;44. \u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"lung cancer, immunotherapy, airway microbiota, antibiotics, corticosteroids","lastPublishedDoi":"10.21203/rs.3.rs-3899720/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3899720/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eLung cancer is a leading cause of morbidity and mortality globally, with its high mortality rate attributed mainly to non-small cell lung cancer (NSCLC). Although immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized its treatment, patient response is highly variable and lacking predictive markers. We conducted a prospective study on 55 patients with NSCLC undergoing ICI therapy to identify predictive markers of both response and immune-related adverse events (IrAEs) in the airway microbiota. We also analyzed the clinical evolution and overall survival (OS) with respect to treatments that affect the integrity of the microbiota, such as antibiotics and corticosteroids. Our results demonstrated that respiratory microbiota differ significantly in ICI responders: they have higher alpha diversity values and lower abundance of the Firmicutes phylum and the \u003cem\u003eStreptococcus\u003c/em\u003e genus. Employing a logistic regression model, the abundance of \u003cem\u003eGemella\u003c/em\u003e was the major predictor of non-ICI response, whereas \u003cem\u003eLachnoanaerobaculum\u003c/em\u003e was the best predictor of a positive response to ICI. The most relevant results were that antibiotic consumption is linked to a lower ICI response, and the use of corticosteroids correlated with poorer overall survival. Whereas previous studies have focused on gut microbiota, our findings highlight the importance of the respiratory microbiota in predicting the treatment response. Future research should explore microbiota modulation strategies to enhance immunotherapy outcomes. Understanding the impact of antibiotics, corticosteroids, and microbiota on NSCLC immunotherapy will help personalize treatment and improve patient outcomes.\u003c/p\u003e","manuscriptTitle":"Impact of Antibiotics, Corticosteroids, and Microbiota on Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-01-30 17:54:51","doi":"10.21203/rs.3.rs-3899720/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"38c057a3-f3a8-4edb-909d-d5e854eb446e","owner":[],"postedDate":"January 30th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-07-03T00:49:33+00:00","versionOfRecord":{"articleIdentity":"rs-3899720","link":"https://doi.org/10.1016/j.heliyon.2024.e33684","journal":{"identity":"heliyon","isVorOnly":true,"title":"Heliyon"},"publishedOn":"2024-07-01 00:49:33","publishedOnDateReadable":"July 1st, 2024"},"versionCreatedAt":"2024-01-30 17:54:51","video":"","vorDoi":"10.1016/j.heliyon.2024.e33684","vorDoiUrl":"https://doi.org/10.1016/j.heliyon.2024.e33684","workflowStages":[]},"version":"v1","identity":"rs-3899720","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3899720","identity":"rs-3899720","version":["v1"]},"buildId":"WrCJVZZCHTDjtuVLN7oU0","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}